Study on estimation of glucose-6-phosphate dehydrogenase in patients prior to initiation of dapsone therapy in leprosy

Manoj Kumar Agarwala; Pragya Agarwala; Archa Sharma

doi:10.18203/issn.2455-4529.IntJResDermatol20193233

Authors

Manoj Kumar Agarwala Department of Dermatology, Chandulal Chandrakar Memorial Medical College, Durg, Chhattisgarh
Pragya Agarwala Department of Microbiology, All India Institute of Medical Science Raipur, Raipur, Chhattisgarh
Archa Sharma Department of Microbiology, Gandhi Medical College, Bhopal, Madhya Pradesh

DOI:

https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20193233

Keywords:

Dapsone, G6PD, Leprosy, India

Abstract

Background: Administration of dapsone in glucose-6-phosphate dehydrogenase (G6PD) deficient patients can lead to hemolysis which may be severe enough to warrant discontinuation of the drug. Screening for G6PD deficiency in leprosy patients before initiating treatment can prevent such adverse events.

Methods: Medical records of all leprosy patients presenting between 1st January 2018 to 30th June 2018 were reviewed. G6PD levels, if done, were recorded for all patients needing dapsone therapy.

Results: Of the 62 patients requiring treatment with dapsone (43 outpatients and 19 inpatients), G6PD estimation was done in 43 cases, i.e., 60.46% (26/43) of outpatients and 89.4% (17/19) of inpatients.10 patients were found deficient (6/26 outpatients and 4/17 inpatients).

Conclusions: G6PD levels were not uniformly estimated in all patients requiring dapsone therapy. It was done more commonly estimated in inpatients (89.4%) when compared to outpatients (60.46%). The deficient G6PD levels were seen in 16% cases.

Metrics

Metrics Loading ...

Author Biography

Manoj Kumar Agarwala, Department of Dermatology, Chandulal Chandrakar Memorial Medical College, Durg, Chhattisgarh

Assistant Professor

Department of Dermatology

References

Wolf R, Tüzün B, Tüzün Y. Dapsone: unapproved uses or indications. Clin Dermatol. 2000;18(1):37–53.

Deps P, Guerra P, Nasser S, Simon M. Hemolytic anemia in patients receiving daily dapsone for the treatment of leprosy. Lepr Rev. 2012;83(3):305–7.

Todd P, Samaratunga IR, Pembroke A. Screening for glucose-6-phosphate dehydrogenase deficiency prior to dapsone therapy. Clin Exp Dermatol. 1994;19(3):217–8.

Sharma M, Dass J, Dhingra B, Saxena R. G6PD deficiency in females screened at tertiary care hospital. Indian J Pathol Microbiol. 2011;54(4):850–1.

Tripathy V, Reddy BM. Present status of understanding on the G6PD deficiency and natural selection. J Postgrad Med. 2007;53(3):193–202.

Banait PP, Junnarkar RV. Study of erythrocyte G6PD deficiency in leprosy. Int J Lepr Other Mycobact Dis. 1971;39(2):168-71.

Kher MM, Solanki BR, Parande CM, Junnarkar RV. Glucose-6-phosphate dehydrogenase deficiency at Nagpur and in surrounding areas: a survey. Indian Med Gaz. 1967;7:34-9.